STOCK TITAN
  1. Home
  2. News
  3. HOOK

HOOKIPA Pharma Inc. - $HOOK STOCK NEWS

Welcome to our dedicated page for HOOKIPA Pharma news (Ticker: $HOOK), a resource for investors and traders seeking the latest updates and insights on HOOKIPA Pharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HOOKIPA Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HOOKIPA Pharma's position in the market.

News
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported positive preliminary Phase 2 data for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer. The data reinforce strong objective response rate and disease control rate reported in Q2 2023. The company also published peer-reviewed preclinical data for HB-400 program in The Journal of Infectious Disease. Recruitment is ongoing for two Phase 1 clinical trials for advanced prostate cancer and chronic hepatitis B. IND-enabling activities are in progress to advance two additional therapeutic candidates into the clinic in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12%
Tags
earnings
-
News
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
Rhea-AI Summary
HOOKIPA Pharma Inc. announced updated Phase 1 clinical data on HB-200 as a monotherapy in patients with recurrent/metastatic HPV16+ head and neck cancer. The data show that HB-200 induced robust tumor-specific T cell responses, with a 44 percent disease control rate in a difficult-to-treat patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
none
-
News
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its third quarter 2023 financial results and business highlights on November 9, 2023. No conference call will be conducted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
conferences earnings
News
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Rhea-AI Summary
HOOKIPA Pharma presents updated data from Phase 2 trial of HB-200 in combination with pembrolizumab for head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
Rhea-AI Summary
HOOKIPA Pharma announces publication of preclinical data on HB-400, a potential therapeutic vaccine for chronic hepatitis B
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
clinical trial
-
News
HOOKIPA Announces Executive Leadership Change
Rhea-AI Summary
HOOKIPA Pharma's Chief Medical Officer, Katia Schlienger, is stepping down to pursue new opportunities, effective September 30. Malte Peters, a current member of the Board of Directors, will lead clinical activities ad interim. Peters has extensive experience in bringing new therapies to patients. HOOKIPA remains focused on executing clinical priorities and progressing their programs with Roche and Gilead.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
management
News
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
HOOKIPA Pharma grants non-statutory options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
News
HOOKIPA Pharma to participate in upcoming investor conferences in September
Rhea-AI Summary
HOOKIPA Pharma Inc. (HOOK) to present at investor conferences and host one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences
-
News
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
HOOKIPA Pharma reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab for advanced head and neck cancer. Recruitment ongoing for two Phase 1 clinical trials. IND-enabling activities in progress for two additional therapeutics. $50 million follow-on offering strengthened cash basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
earnings
News
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
conferences earnings
Stock HOOK logo
HOOKIPA Pharma Inc.

Nasdaq:HOOK

HOOK Rankings

#4350 Ranked by Market Cap
#5063 Ranked by Stock Gains
N/A Ranked by Dividends

HOOK Stock Data

92.04M
58.31M
19.59%
39.38%
0.32%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
NEW YORK

About HOOK

hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a